[{"address1": "230 Park Avenue", "address2": "Suite 3350", "city": "New York", "state": "NY", "zip": "10169", "country": "United States", "phone": "646 885 8505", "website": "https://www.ymabs.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.", "fullTimeEmployees": 100, "companyOfficers": [{"maxAge": 1, "name": "Mr. Thomas  Gad", "age": 53, "title": "Founder, Chief Business Officer & Vice Chairman", "yearBorn": 1970, "fiscalYear": 2022, "totalPay": 1047496, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bo  Kruse", "age": 51, "title": "Executive VP, Secretary, Treasurer & CFO", "yearBorn": 1972, "fiscalYear": 2022, "totalPay": 685021, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan  Smith", "age": 52, "title": "Senior VP & Chief Commercial Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": 710000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Michael  Rossi", "age": 52, "title": "CEO, President & Director", "yearBorn": 1971, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joris Wiel Jan Wilms", "age": 49, "title": "Senior VP & COO", "yearBorn": 1974, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Torben  Lund-Hansen M.Sc., Ph.D.", "age": 72, "title": "Senior VP & CTO", "yearBorn": 1951, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Steen  Lisby M.D., M.Sc.", "age": 59, "title": "Senior VP & Chief Scientific Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 393985, "exercisedValue": 0, "unexercisedValue": 274400}], "auditRisk": 4, "boardRisk": 8, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1709251200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 2, "previousClose": 17.99, "open": 18.04, "dayLow": 17.45, "dayHigh": 18.165, "regularMarketPreviousClose": 17.99, "regularMarketOpen": 18.04, "regularMarketDayLow": 17.45, "regularMarketDayHigh": 18.165, "beta": 0.746, "forwardPE": -51.88235, "volume": 136502, "regularMarketVolume": 136502, "averageVolume": 401366, "averageVolume10days": 404720, "averageDailyVolume10Day": 404720, "bidSize": 1400, "askSize": 1300, "marketCap": 772228032, "fiftyTwoWeekLow": 2.7, "fiftyTwoWeekHigh": 20.9, "priceToSalesTrailing12Months": 9.104423, "fiftyDayAverage": 12.06, "twoHundredDayAverage": 7.66565, "currency": "USD", "enterpriseValue": 695010112, "profitMargins": -0.25261998, "floatShares": 27534924, "sharesOutstanding": 43777100, "sharesShort": 2202311, "sharesShortPriorMonth": 2131401, "sharesShortPreviousMonthDate": 1705017600, "dateShortInterest": 1707955200, "sharesPercentSharesOut": 0.0504, "heldPercentInsiders": 0.14551, "heldPercentInstitutions": 0.61971, "shortRatio": 4.56, "shortPercentOfFloat": 0.060599998, "impliedSharesOutstanding": 43777100, "bookValue": 2.312, "priceToBook": 7.6297574, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -21427000, "trailingEps": -0.49, "forwardEps": -0.34, "pegRatio": 0.44, "enterpriseToRevenue": 8.194, "enterpriseToEbitda": -33.978, "52WeekChange": 4.5869565, "SandP52WeekChange": 0.3219322, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "YMAB", "underlyingSymbol": "YMAB", "shortName": "Y-mAbs Therapeutics, Inc.", "longName": "Y-mAbs Therapeutics, Inc.", "firstTradeDateEpochUtc": 1537536600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ef4c7aed-ff51-3117-8a16-0b2c87e3c948", "messageBoardId": "finmb_378585331", "gmtOffSetMilliseconds": -18000000, "currentPrice": 17.64, "targetHighPrice": 26.0, "targetLowPrice": 10.0, "targetMeanPrice": 20.0, "targetMedianPrice": 22.0, "recommendationMean": 2.1, "recommendationKey": "buy", "numberOfAnalystOpinions": 7, "totalCash": 78637000, "totalCashPerShare": 1.796, "ebitda": -20455000, "totalDebt": 1419000, "quickRatio": 5.022, "currentRatio": 5.52, "totalRevenue": 84819000, "debtToEquity": 1.405, "revenuePerShare": 1.943, "returnOnAssets": -0.09835, "returnOnEquity": -0.20387, "freeCashflow": -14034750, "operatingCashflow": -27232000, "revenueGrowth": -0.257, "grossMargins": 0.86541003, "ebitdaMargins": -0.24115999, "operatingMargins": -0.13693, "financialCurrency": "USD", "trailingPegRatio": null}]